A majority of educators say their districts’ career and technical education offerings are increasing, driven in large part by growing student demand. That’s according to an EdWeek Research Center ...

New research shows that CTE may stem from DNA damage and inflammation set in motion by blows to the head. When you purchase through links on our site, we may earn an affiliate commission. Here’s how ...

The NFL season has been rife with tragedy—not that the league or its media partners have noticed. Cleveland Browns player Carl Nassib enters the bue tent during an NFL football game against the New ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

This story mentions suicide. Mental health resources can be found at the bottom of this story. The death of Dallas Cowboys defensive end Marshawn Kneeland from an apparent self-inflicted gunshot wound ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

The neurologic disease called chronic traumatic encephalopathy or CTE has most often been found in people who experienced repeated blows to the head while playing contact sports and there’s now ...

In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...

Late last month, the New York City medical examiner confirmed the man who shot and killed four people at a Manhattan office tower had the degenerative brain disease Chronic Traumatic Encephalopathy, ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...